Evidence map›Paper›PMID 28873442›Full record

ArticlePLoS neglected tropical diseases2017

Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells.

Rosângela Salerno-Gonçalves, Hervé Tettelin, David Lou, Stephanie Steiner, Tasmia Rezwanul, Qin Guo, William D Picking, Vishvanath Nene, Marcelo B Sztein

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Association betweenHuman vaccines & immunotherapeutics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rosângela Salerno-GonçalvesCenter for Vaccine Development (CVD), Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.ORCID http://orcid.org/0000-0003-2999-4275
Hervé TettelinDepartment of Microbiology and Immunology and Institute for Genome Sciences (IGS), University of Maryland School of Medicine, Baltimore, MD, United States of America.
David LouCenter for Vaccine Development (CVD), Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Stephanie SteinerDepartment of Microbiology and Immunology and Institute for Genome Sciences (IGS), University of Maryland School of Medicine, Baltimore, MD, United States of America.
Tasmia RezwanulCenter for Vaccine Development (CVD), Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Qin GuoDepartment of Microbiology and Immunology and Institute for Genome Sciences (IGS), University of Maryland School of Medicine, Baltimore, MD, United States of America.
William D PickingDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas, United States of America.
Vishvanath NeneInternational Livestock Research Institute (ILRI), Nairobi, Kenya.
Marcelo B SzteinCenter for Vaccine Development (CVD), Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SZTEIN, MARCELO B. · 2009 to 2018
$27.8M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
NIAID NIH HHS R01 AI036525NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI109776
6 · The paper itself

Abstract

Salmonella enterica serovar Typhi (S. Typhi), the causative agent of the typhoid fever, is a pathogen of great public health importance. Typhoid vaccines have the potential to be cost-effective measures towards combating this disease, yet the antigens triggering host protective immune responses are largely unknown. Given the key role of cellular-mediated immunity in S. Typhi protection, it is crucial to identify S. Typhi proteins involved in T-cell responses. Here, cells from individuals immunized with Ty21a typhoid vaccine were collected before and after immunization and used as effectors. We also used an innovative antigen expressing system based on the infection of B-cells with recombinant Escherichia coli (E. coli) expressing one of four S. Typhi gene products (i.e., SifA, OmpC, FliC, GroEL) as targets. Using flow cytometry, we found that the pattern of response to specific S. Typhi proteins was variable. Some individuals responded to all four proteins while others responded to only one or two proteins. We next evaluated whether T-cells responding to recombinant E. coli also possess the ability to respond to purified proteins. We observed that CD4+ cell responses, but not CD8+ cell responses, to recombinant E. coli were significantly associated with the responses to purified proteins. Thus, our results demonstrate the feasibility of using an E. coli expressing system to uncover the antigen specificity of T-cells and highlight its applicability to vaccine studies. These results also emphasize the importance of selecting the stimuli appropriately when evaluating CD4+ and CD8+ cell responses.

Indexed as

Antigen PresentationAdultAntigens, BacterialBacterial ProteinsEscherichia coliFemaleFlow CytometryHumansMaleMiddle AgedPolysaccharides, BacterialRecombinant ProteinsSalmonella typhiT-LymphocytesTyphoid-Paratyphoid VaccinesVolunteersAntigens, BacterialBacterial ProteinsPolysaccharides, BacterialRecombinant ProteinsTy21a typhoid vaccineTyphoid-Paratyphoid Vaccines

Identifiers

PMID28873442
PMCPMC5600385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.